A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 1, 2005, Pages 52-57

  Nayak, Tapan ^a   Norenberg, Jeffrey ^a   Anderson, Tamara ^a   Atcher, Robert ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

Apoptosis; Linear energy transfer; Preclinical cellular dosimetry; Somatostatin receptor radionucleotide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; OCTREOTIDE[1,4,7 TETRAAZADODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE] BI 213; OCTREOTIDE[1,4,7 TETRAAZADODECANE 1,4,7,10 TETRAACETIC ACID 3 TYROSINE] LU 177; OCTREOTIDE[3 TYROSINE]; RADIOISOTOPE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ABSORPTION; APOPTOSIS; CELL DEATH; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENCY; DRUG TARGETING; ENERGY TRANSFER; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL TEST; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RADIOBIOLOGY; RADIOSENSITIVITY; STATISTICAL SIGNIFICANCE; TECHNIQUE;

ACTINIUM; ALPHA PARTICLES; APOPTOSIS; BETA RAYS; BISMUTH; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENERGY TRANSFER; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIGANDS; LUTETIUM; MITOSIS; MODELS, STATISTICAL; NEOPLASMS; OCTREOTIDE; RADIOISOTOPES; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN;

EID: 16444385850     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.52     Document Type: Conference Paper

References (17)

1. 90Y: Peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm 2003;18:761.
2. Krenning EP, Kwekkeboom DJ, Valkema R, et al. Peptide receptor radionuclide therapy. Ann NY Acad Sci 2004;1014:234.
3. Breeman WA, Bakker WH, de Jong M, et al. Studies on radiolabeled somatostatin analogs in rats and in patients. Q J Nucl Med 1996;40:209.
4. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389.
5. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439.
6. 90Y-DOTATOC. Eur J Nucl Med Mol Imaging 2002;29:435.
7. Lewington VJ. Targeted radionuclide therapy for neuroendocrine tumors. Endocr Relat Cancer 2003;10:497.
8. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1341.
9. 3] octreotide (bi-DOTATOC) in peptide receptor radionuclide therapy (PRRT): Radiolabeling, stability, and biodistribution. Nucl Med Commun 1999;20:383.
10. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917.
11. 212Bi alpha particle irradiation. Nucl Med Biol 1993;20:795.
12. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer 2002;86:1197.
13. Fisher DR, Harty R. The microdosimetry of lymphocytes irradiated by alpha-particles. Int J Radiat Biol Relat Stud Phys Chem Med 1982;41:315.
14. Murty Goddu S, Howell RW, Bouchet LG, et al. MIRD Cellular S Values: Self-Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Monoenergetic Electron and Alpha Particle Emitters Incorporated into Different Cell Compartments. Reston, Virginia: Society of Nuclear Medicine, 1997.
15. Allen BJ, Blagojevic N. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: The potential role of terbium-149. Nucl Med Commun 1996;17:40.
16. Lloyd EL, Gemmell MA, Henning CB, et al. Cell survival following multiple-track alpha particle irradiation. Int J Radiat Biol Relat Stud Phys Chem Med 1979;35:23.
17. Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res 2000;301:133.